Abstract
The following work compared adverse effects profile and patients’ acceptability of intra-venous oxytocin 10 iu and oral misoprostol 600 ug used in the prevention of postpartum hemorrhage in the third stage of labour. A total of 1865 pregnant women who have received either oxytocin injection or oral misoprostol in third stage of labour as prophylaxis for postpartum haemorrhage, were enrolled within three health care facilities in Maiduguri, Nigeria. Each patient was observed at parturition and for 24 h after during which oral interviews were conducted and clinical notes studied. The oxytocin medication group exhibited higher abdominal pains (7.1% versus 0.0%; p 0.05) difference in patients acceptability of injectable oxytocin (99.3%) and oral misoprostol (98.3%). Oxytocin usage in the prevention of PPH was associated with abdominal pains and headache while misoprostol was associated with shivering and fever. Patients from this study have demonstrated high level of acceptability of both parenteral oxytocin and oral misopristol prevention of post-partum haemorrhage.
Highlights
The leading cause of Postpartum Haemorrhage (PPH) is uterine atony, which is generally preventable by the use of uterotonics, among which oxytocin is preferred in hospital-based settings [1,2,3]
There were no significant differences in other side effects like nausea and vomiting
Patients from this study have demonstrated high level of acceptability of both parenteral oxytocin and oral misopristol prevention of post-partum haemorrhage
Summary
The leading cause of Postpartum Haemorrhage (PPH) is uterine atony, which is generally preventable by the use of uterotonics, among which oxytocin is preferred in hospital-based settings [1,2,3]. Use of oxytocin has a lot of limitations in low-income countries where births still occur at home with untrained birth attendants who do not practice active management of the third stage of labour (AMTSL) [2,4,5,6,7]. Other uterotonic agents such as oral misoprostol have been shown to be effective for the prevention of PPH but its use have been limited by incidences of adverse effects like shivering and vomiting, and as such it is yet to be implemented as standard care in low-resource settings [8,9]. The idea of defining a more suitable (perhaps more patient friendly) misoprostol route, and comparing its adverse effects with that of the conventional parenteral oxytocin, is a crucial therapeutic issue
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
